Although siponimod is 99.9% bound to plasma proteins and unlikely to reach the breastmilk in large amounts, it is potentially toxic to the breastfed infant. Because there is no published experience with siponimod during breastfeeding, expert opinion generally recommends that the closely related drug fingolimod should be avoided during breastfeeding, especially while nursing a newborn or preterm infant.[1-6] However, the manufacturer's labeling does not recommend against the use of siponimod in breastfeeding.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: A systematic review. Obstet Gynecol 2014;124:1157-68. [PubMed: 25415167]
2.
Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler 2013;19:835-43. [PubMed: 23319073]
3.
Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: Therapeutic considerations. J Neurol 2013;260:1202-14. [PubMed: 22926165]
4.
Almas S, Vance J, Baker T, et al. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int 2016;2016:6527458. [PMC free article: PMC4757692] [PubMed: 26966579]
5.
Kaplan TB. Management of demyelinating disorders in pregnancy. Neurol Clin 2019;37:17-30. [PubMed: 30470273]
6.
Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol 2019;19:106-14. [PubMed: 30612100]
Substance Identification
Substance Name
Siponimod
CAS Registry Number
1230487-00-9
Drug Class
Breast Feeding
Lactation
Milk, Human
Immunosuppressive Agents
Sphingosine 1 Phosphate Receptor Modulators
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
